| Active ingredient (INN) | Abraxane |
|---|---|
| ATC level 5 | L01CD01 |
| ATC level 4 | L01CD |
| Therapeutic category | Auto-created by Swissmedic scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Abraxis Bioscience Australia Pty Ltd, Abraxis BioScience, LLC, Bristol-Myers Squibb Pharma EEIG, BRISTOL-MYERS SQUIBB CANADA |
|---|
| Registrations on file | 5 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| ABRAXANE nanoparticle albumin-bound paclitaxel | 100 mg | — | 🇦🇺 AU | Abraxis Bioscience Australia Pty Ltd | Active |
| ABRAXANE nanoparticle albumin-bound paclitaxel | 250 mg | — | 🇦🇺 AU | Abraxis Bioscience Australia Pty Ltd | Active |
| ABRAXANE | 100mg/20mL | injection | 🇺🇸 US | Abraxis BioScience, LLC | Active |
| Abraxane | — | — | 🌐 EU | Bristol-Myers Squibb Pharma EEIG | Active |
| Abraxane For | — | suspension | 🇨🇦 CA | BRISTOL-MYERS SQUIBB CANADA | Active |